<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04202510</url>
  </required_header>
  <id_info>
    <org_study_id>IRB #19-869</org_study_id>
    <nct_id>NCT04202510</nct_id>
  </id_info>
  <brief_title>IOP and Medication Reduction in MIGS Procedures</brief_title>
  <official_title>Pressure Reduction and Medication Use Following Different Minimally Invasive Glaucoma Surgery Procedures, Prospective Randomized Clinical Trial of Efficacy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wills Eye</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tanta Medical School, Tanta University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wills Eye</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this research is to compare the efficacy of trabecular minimally
      invasive glaucoma surgery (MIGS) devices (iStent vs iStent Inject vs Hydrus) for intra ocular
      pressure (IOP) and anti-glaucoma medication reduction in open angle glaucoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design Prospective Randomized Clinical Trial (Parallel Group Study)

      Patients who fit inclusion criteria will be randomly assigned to one of the 3 parallel groups
      (one of the study surgical interventions combined with phacoemulsification) in the following
      order:

        1. 1st Generation iStent, Trabecular Micro-Bypass Device (Glaukos Inc, San Clemente, CA).

        2. 2nd Generation iStent, Trabecular Micro-Bypass Device (Glaukos Inc, San Clemente, CA).

        3. Hydrus Microstent (Ivantis Inc, Irvine, CA). Blocked randomization will be used in 1:1:1
           ratio to provide balanced study groups. Allocation will be performed using a random
           number table.

      Preoperative Evaluation of : Visual acuity, Slit lamp examination, IOP, Gonioscopy, Fundus
      Examination, Central corneal thickness (CCT), Endothelial Cell Count (ECC), Visual field,
      Retinal Nerve Fiber layer (RNFL) thickness by Optical Coherence Tomography (OCT) and Number
      and type of preoperative antiglaucoma medications.

      Patients will be followed postoperatively at Day 1, Week 1, Months 1, 3, 6 and 12.

      Medication Washout will be done at baseline, Months 6 and 12 to evaluate non-medicated IOP.

      The duration of washout will be:

      4 Weeks for Prostaglandin Analogues (PGA) and Beta Blockers (BB). 2 Weeks for Carbonic
      Anhydrase Inhibitors (CAI) and Alpha Agonists (AA).

      The IOP measurements in the wash out visits:

      will be performed according to 2-operator method to provide masking as described in Ocular
      Hypertension Treatment Study (OHTS) and Glaucoma World Association Guidelines.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 6, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular Pressure (IOP)</measure>
    <time_frame>1 hour examination at Baseline, Day 1, Week 1, Months 1, 3, 6 and 12</time_frame>
    <description>Reduction of IOP after eye surgery measured in millimeters of mercury (mmHg)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>1 hour examination at Baseline, Day 1, Week 1, Months 1, 3, 6 and 12</time_frame>
    <description>Change in visual acuity after eye surgery measured in minimal angle of resolution (logMAR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central Corneal Thickness (CCT)</measure>
    <time_frame>1 hour examination at Baseline, Months 3, 6 and 12</time_frame>
    <description>Change in CCT after eye surgery measured in microns using pachymeter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial Cell Count</measure>
    <time_frame>1 hour examination at Baseline, Months 3, 6 and 12</time_frame>
    <description>Change in endothelial cell count after eye surgery measured in number of cells by millimeter square using specular microscopy.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Open Angle Glaucoma</condition>
  <condition>Primary Open Angle Glaucoma</condition>
  <condition>Pigmentary Glaucoma</condition>
  <condition>Pseudoexfoliation Glaucoma in Both Eyes</condition>
  <arm_group>
    <arm_group_label>iStent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>iStent Trabecular Bypass Device (to lower intraocular pressure) combined with Phacoemulsification (to remove cataract and insert intraocular lens) Eye Surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>iStent Inject</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>iStent Inject Trabecular Bypass Device (to lower intraocular pressure) combined with Phacoemulsification (to remove cataract and insert intraocular lens) Eye Surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydrus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hydrus Trabecular Bypass Device (to lower intraocular pressure) combined with Phacoemulsification (to remove cataract and insert intraocular lens) Eye Surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Glaucoma and Cataract Surgery</intervention_name>
    <description>Patients requiring combined cataract and glaucoma surgery will be randomized to either iStent, iStent Inject or Hydrus (to lower intraocular pressure) combined with Phacoemulsification (to remove cataract and insert intraocular lens) Eye Surgery</description>
    <arm_group_label>Hydrus</arm_group_label>
    <arm_group_label>iStent</arm_group_label>
    <arm_group_label>iStent Inject</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Adult male or female aged 40 years or more. 2. Patients able and willing to provide
             informed consent. 3. Patients having Visually Significant Age Related Cataract with
             Mild to Moderate Open Angle Glaucoma (OAG) on topical anti-glaucoma medication with or
             without previous Selective Laser Trabeculoplasty (SLT) ), including:

               1. Primary open angle glaucoma (POAG).

               2. Pigmentary glaucoma.

               3. Pseudoexfoliative glaucoma. 4. Patients should be candidate for safe mediaction
                  wash out in the opinion of the investigator.

                    -  The diagnosis of glaucoma is confirmd by optic nerve examination and the
                       characteristic visual field defects on automated perimetry according to the
                       American Academy of Ophthalmology (AAO) Definition and Criteria.

                    -  The severity of glaucoma is classified using the Hodapp Parrish Anderson
                       Visual Field Criteria depending on the Mean Deviation (MD):

                         1. Mild: MD no worse than -6 dB.

                         2. Moderate: MD worse than -6 but no worse than -12 dB.

                         3. Severe: MD worse than -12 dB.

        Exclusion Criteria:

          1. Glaucoma types rather than open angle glaucoma types mentioned in the inclusion
             criteria (Primary, Pigmentary and Pseudoexfoliation Glaucomas).

          2. Any prior glaucoma, corneal or vitreoretinal surgery.

          3. Evidence of concomitant retinal, optic nerve, or neurological diseases affecting the
             visual field.

          4. Abnormal angle anatomy.

          5. Prior Argon Laser Trabeculoplasty (ALT), Laser Iridotomy or Iridoplasty.

          6. Any systemic condition or medications affectiong IOP.

          7. Corneal opacity, corneal dystrophy or central corneal thickness (CCT) less than 480 or
             more than 620 microns.

          8. Exclusion from medications wash out according to the opinion of the investigator Or if
             any of the following is observed at any time point of the study:

               1. Visual Field: Mean deviation worse than -12 dB.

               2. Intraocular pressure: a treated IOP of greater than 24 mmHg.

               3. Medications: using more than three medications.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wills Eye Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wesam M Shalaby, MD</last_name>
    <phone>215-928-3123</phone>
    <email>wshalaby@willseye.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lillian Nguyen, BS</last_name>
    <phone>215-928-3123</phone>
    <email>lNguyen@willseye.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Wills Eye Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeanne L Molineaux, COA</last_name>
      <phone>215-825-4713</phone>
      <email>jmolineaux@willseye.org</email>
    </contact>
    <investigator>
      <last_name>Michael Pro, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathan Myers, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Scott Fudemberg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marlene R Moster, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Natasha Kolomeyer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wesam Shalably, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aakriti Shukla, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>M Reza Razeghinejad, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anand Mantravadi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elizabeth Dale, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 11, 2019</study_first_submitted>
  <study_first_submitted_qc>December 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2019</study_first_posted>
  <last_update_submitted>January 9, 2020</last_update_submitted>
  <last_update_submitted_qc>January 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wills Eye</investigator_affiliation>
    <investigator_full_name>Daniel Lee, MD</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Exfoliation Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

